GLP-1 Research Tracker

Every clinical trial and published study on semaglutide, tirzepatide, and next-generation GLP-1 medications — curated with plain-language summaries.

234 studies tracked·6 compounds covered·Updated Jul 2026

Has results

GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes.

Metabolism openMar 2026

Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice.

liraglutide

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieMar 2026

Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population.

semaglutidetirzepatide

Journal of managed care & specialty pharmacyMar 2026

Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.

semaglutidetirzepatide

Journal of managed care & specialty pharmacyMar 2026

Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health.

tirzepatide

Urology case reportsMar 2026

A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition.

semaglutide

Obesity reviews : an official journal of the International Association for the Study of ObesityMar 2026

Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues.

semaglutide

Molecular metabolismMar 2026

Metformin and beyond: glucose-lowering therapy as a potential modulator of abdominal aortic aneurysm growth and stability- systematic review with narrative synthesis.

Cardiovascular diabetology. Endocrinology reportsMar 2026

Association of GLP-1 Receptor Agonist and SGLT2 Inhibitor with Cardiovascular Outcomes after Transcatheter Aortic Valve Replacement.

The American journal of cardiologyFeb 2026

Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study.

semaglutidetirzepatideliraglutide

Naunyn-Schmiedeberg's archives of pharmacologyFeb 2026

Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis.

tirzepatide

Cardiovascular diabetologyFeb 2026

Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.

semaglutidetirzepatide

Diabetes, obesity & metabolismFeb 2026

Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions.

semaglutideliraglutide

Communications medicineFeb 2026

Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis.

semaglutideliraglutide

International journal of surgery (London, England)Feb 2026

Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

semaglutidetirzepatideliraglutide

International journal of clinical pharmacyFeb 2026

Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023.

semaglutide

Obesity (Silver Spring, Md.)Feb 2026

Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study.

The lancet. Diabetes & endocrinologyFeb 2026

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.

semaglutide

The American journal of cardiologyFeb 2026

Pharmacological strategies to prevent cancer therapy-related cardiovascular toxicity: the road to personalised cardioprotection.

Heart (British Cardiac Society)Feb 2026

Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.

semaglutidetirzepatide

Obesity (Silver Spring, Md.)Feb 2026

Load more studies →

GLP-1 Research Tracker

GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes.

Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice.

Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population.

Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.

Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health.

A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition.

Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues.

Metformin and beyond: glucose-lowering therapy as a potential modulator of abdominal aortic aneurysm growth and stability- systematic review with narrative synthesis.

Association of GLP-1 Receptor Agonist and SGLT2 Inhibitor with Cardiovascular Outcomes after Transcatheter Aortic Valve Replacement.

Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study.

Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis.

Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.

Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions.

Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis.

Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023.

Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study.

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.

Pharmacological strategies to prevent cancer therapy-related cardiovascular toxicity: the road to personalised cardioprotection.

Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.

Get Weekly Research Updates